In a press release, the company writes that it will simplify its organization and relocate resources. Currently, it has 78,400 employees.
"While the market has changed, particularly when it comes to overweight, and become more consumption-driven and competitive, our company must also develop," says Mike Doustdar, CEO of Novo Nordisk in a press release.
The cuts will mean annual savings of eight billion Danish kronor by the end of 2026. This is happening at the same time as the company is now lowering its profit forecast for 2025. On the Copenhagen Stock Exchange, the message also has a positive effect on the share, which rises 2.5 percent, but since the turn of the year, it is still down 44 percent.
The Danish pharmaceutical company has in recent years grown to become one of Europe's largest companies thanks to the success of, among other things, Ozempic, which has proven to be very successful when it comes to weight loss.
However, in recent times, competition has intensified, particularly from the American Eli Lilly as well as copies of Ozempic. Last month, it was announced that CEO Lars Fruergaard Jørgensen will be replaced by Mike Doustdar.
